STEPHEN A UDEM
Medical Practice in New York, NY

2003012, Jul 10, 2003

Oct 1, 2002

10/261961

Christopher Parks - Boonton NJ, US
Mohinderjit Sidhu - Scotch Plains NJ, US
Stephen Udem - New York NY, US
Gerald Kovacs - Morristown NJ, US

Wyeth - Madison NJ

C12N007/02, C07H021/04, C12N007/00, C12N007/01, C12N015/00, C12N015/09, C12N015/63, C12N015/70, C12N015/74

435/239000, 435/235100, 536/023720, 435/320100

This invention relates to improved methods for producing nonsegmented, negative-sense, single-stranded RNA viruses of the Order designated Mononegavirales virus, including embodiments relating to methods of producing such viruses as attenuated and/or infectious viruses, such as Measles virus (MV) and respiratory syncytial virus (RSV). One method for producing a recombinant virus from the Order Mononegavirales comprises (a) in at least one host cell, conducting transfection of a rescue composition which comprises (i) a transcription vector comprising an isolated nucleic acid molecule which comprises polynucleotide sequence encoding a genome or antigenome of a nonsegmented, negative-sense, single stranded RNA virus of the Order Mononegavirales and (ii) at least one expression vector which comprises at least one isolated nucleic acid molecule encoding the trans-acting proteins necessary for encapsidation, transcription and replication; in a host cell under conditions sufficient to permit the co-expression of these vectors and the production of the recombinant virus; (b) heating the transfected rescue composition to an effective heat shock temperature under conditions sufficient to increase the recovery of the recombinant virus; and optionally, (c) harvesting the resulting recombinant virus.

2005008, Apr 28, 2005

Jun 22, 2001

10/312052

Christopher Parks - Boonton NJ, US
Mohinderjit Sidhu - New City NY, US
Pramila Walpita - Basking Ridge NJ, US
Gerald Kovacs - Ridgewood NJ, US
Stephen Udem - New York NY, US

C12N007/00, C12N015/86

435235100, 435456000

This invention relates to a method for recombinantly producing via rescue canine distemper virus, a nonsegmented, negative-sense, single-stranded RNA virus, and immunogenic compositions formed therefrom. Additional embodiments relate to methods of producing the canine distemper virus as an attenuated and/or infectious viruses. The recombinant viruses can be prepared from cDNA clones, and, accordingly, viruses having defined changes, including nucleotide/polynucleotide deletions, insertions, substitutions and rearrangements, in the genome can be obtained.

7361496, Apr 22, 2008

Aug 2, 2000

10/048384

David K. Clarke - Chester NY, US
J. Erik Johnson - Verona NJ, US
Mohinderjit S. Sidhu - Scotch Plains NJ, US
Stephen A. Udem - New York NY, US

Wyeth - Madison NJ

C12N 7/00

4352351, 435 691, 4353201, 435239, 435455, 435456, 435471, 435476

This invention relates to a method for recombinantly producing, via rescue of mumps virus, a nonsegmented, negative-sense, single-stranded RNA virus, and immunogenic compositions formed therefrom. Additional embodiments relate to methods of producing the mumps virus as an attenuated and/or infectious virus. The recombinant viruses are prepared from cDNA clones, and, accordingly, viruses having defined changes, including nucleotide/polynucleotide deletions, insertions, substitutions and re-arrangements, in the place of the genome are obtained.

2012024, Sep 27, 2012

Apr 24, 2012

13/454884

John Eldridge - Somers NY, US
Zimra R. Israel - New York NY, US
Michael A. Egan - Washingtonville NY, US
Stephen A. Udem - New York NY, US

WYETH LLC - Madison NJ

A61K 39/21, A61P 31/14, A61P 31/18, A61P 37/04, A61K 38/19, A61K 38/20

424 852, 4241991, 424 851

A method of inducing an antigen-specific immune response in a mammalian subject includes the steps of administering to the subject an effective amount of a first composition comprising a DNA plasmid comprising a DNA sequence encoding an antigen under the control of regulatory sequences directing expression thereof in a mammalian or vertebrate cell. The method also includes administering to the subject an effective amount of a second composition comprising a recombinant vesicular stomatitis virus (rVSV) comprising a nucleic acid sequence encoding the antigen under the control of regulatory sequences directing expression thereof in the mammalian or vertebrate cell. The rVSV is in one embodiment replication competent. Kits for use in immunizations and therapeutic treatments of disease include the components and instructions for practice of this method.

8647638, Feb 11, 2014

Aug 31, 2012

13/600289

David Kirkwood Clarke - Chester NY, US
Roger Michael Hendry - Atlanta GA, US
Stephen A. Udem - New York NY, US
Christopher Lee Parks - Boonton NJ, US

Wyeth LLC - Madison NJ

A61K 39/205, A61K 39/12, C12N 7/01, C12N 15/63

4242241, 4241991, 4352351, 4353201

The present invention broadly relates to the synergistic attenuation of vesicular stomatitis virus (VSV), More particularly, the invention relates to the identification of combined mutation classes which synergistically attenuate the pathogenicity of VSV vectors in mammals and immunogenic compositions thereof.

2009024, Oct 1, 2009

Feb 3, 2009

12/365122

Deborah A. Buonagurio - Rye NY, US
Alice F. Georgiu - Montgomery NY, US
Robert A. Lerch - New Hempstead NY, US
Bruce B. Mason - Downington PA, US
Shridhara C. Murthy - Ann Arbor MI, US
Ruth S. Rappaport - Strafford PA, US
Mohinder S. Sidhu - New City NY, US
Stephen A. Udem - New York NY, US
Timothy J. Zamb - Nyack NJ, US

Services - Rockville MD

C12P 21/02, C12N 15/11, C12N 15/00, C12N 1/21, C12N 5/00, C12N 1/19, C12N 5/06

435 691, 536 2372, 4353201, 43525233, 435348, 4352542, 435358, 435365

Isolated nucleic acid molecules comprising a gene segment from a rhesus rotavirus (RRV) or from one of three rhesus:human reassortant viruses are disclosed, including isolated nucleic acid molecules having a sequence selected from the group consisting of: SEQ ID NO: 1-14, inclusive, and isolated nucleic acid molecules encoding a protein having a sequence selected from the group consisting of SEQ ID NO: 15-28, inclusive, as well as variants of the isolated nucleic acid molecules.

8287878, Oct 16, 2012

Apr 5, 2005

11/547236

David Kirkwood Clarke - Chester NY, US
Roger Michael Hendry - Warwick NY, US
Stephen A. Udem - New York NY, US
Christopher Lee Parks - Boonton NJ, US

Wyeth LLC - Madison NJ

A61K 39/12, C12N 7/01

4241991, 4352351, 4353201

The present invention broadly relates to the synergistic attenuation of vesicular stomatitis virus (VSV). More particularly, the invention relates to the identification of combined mutation classes which synergistically attenuate the pathogenicity of VSV vectors in mammals and immunogenic compositions thereof.

2007025, Nov 8, 2007

Jun 27, 2007

11/823309

David Clarke - Chester NY, US
J. Johnson - Verona NJ, US
Mohinderjit Sidhu - Scotch Plains NJ, US
Stephen Udem - New York NY, US

Wyeth - Madison NJ

A61K 39/165, A61K 39/295

424202100, 424212100

This invention relates to a method for recombinantly producing, via rescue of mumps virus, a nonsegmented, negative-sense, single-stranded RNA virus, and immunogenic compositions formed therefrom. Additional embodiments relate to methods of producing the mumps virus as an attenuated and/or infectious virus. The recombinant viruses are prepared from cDNA clones, and, accordingly, viruses having defined changes, including nucleotidelpoly/nucleotide deletions, insertions, substitutions and re-arrangements, in the place of the genome are obtained.

7541038, Jun 2, 2009

Jun 2, 2004

10/559429

Gerald Raul Kovacs - Potomac MD, US
Xiaoyan Mo - Boxborough MA, US
Nikolaos Vasilakis - Galveston TX, US
Sangeeta Bhargava - Potomac MD, US
Timothy Joseph Zamb - Nyack NY, US
Stephen Alexander Udem - New York NY, US

Wyeth Holdings Corporation - Madison NJ

A61K 39/155, C12N 15/86

4241991, 4242111, 4353201, 4352351

Self-propagating, fusogenic blebs are produced from cells infected with a population of Venezuelan Equine Encephalitis virus replicon particles (VRP). The self-propagating, fusogenic nature of the blebs is derived from expression of heterologous genes encoding viral fusion proteins that are incorporated into the replication defective replicon particles. The resulting blebs can be harvested from supernatants of cells displaying severe cytopathic effects. The blebs are used to make immunogenic compositions and devise methods of immunizing mammals against paramyxoviruses such as parainfluenza virus type 3.